中国科学院生物与化学交叉研究中心

设为首页 |中文版

研究团队

您的位置: 首页 > 研究团队 > 谭立课题组 > 发表文章
发表文章

代表论文:

(1).Shan H#, Liu J#, Shen J#, Dai J#, Xu G#, Lu K, Han C, Wang Y, Xu X, Tong Y, Zhuang G, Hu J, Zhang Z*, Li Y*, Pan L* and Tan L*. Development of potent and selective inhibitors targeting 1 the papain-like protease of SARS-CoV-2. Cell Chem. Biol., 2021, 28(6):855.

(2). Meng H#, Wu G#, Zhao X#, Wang A#, Li D, Tong Y, Jin T, Cao Y, Shan B, Hu S, Li Y, Pan L, Tian X, Wu P, Peng C, Yuan J, Li G*, Tan L*, Wang Z*, Li Y*. Discovery of a cooperative mode of inhibiting RIPK1 kinase. Cell Discov., 2021, 7(1):41. 

(3).Yang G, Wang J, Tan L, Munshi M, Liu X, Kofides A, Chen JG, Tsakmaklis N, Demos MG, Guerrera ML, Xu L, Hunter ZR, Che J, Patterson CJ, Meid K, Castillo JJ, Munshi NC, Anderson KC, Cameron M, Buhrlage SJ, Gray NS, Treon SP. The HCK/BTK inhibitor KIN-8194 is active in MYD88 driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance. Blood, 2021, doi: 10.1182/blood.2021011405.

(4).Zhang Y, Yu M, Jing Y, Cheng J, Zhang C, Cheng L, Lu H, Cai MC, Wu J, Wang W, Lou W, Qiu L, Tan L, Lu H, Yin X, Zhuang G, Di W. Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer. Br. J. Cancer, 2021, 124(2):414.

(5).Remenyi J, Naik RJ, Wang J, Razsolkov M, Verano A, Cai Q, Tan L, Toth R, Raggett S, Baillie C, Traynor R, Hastie CJ, Gray NS, Arthur JSC. Generation of a chemical genetic model for JAK3. Sci. Rep., 2021, 11(1):10093.

(6).Donovan KA, Ferguson FM, Bushman JW, Eleuteri NA, Bhunia D, Ryu S, Tan L, Shi K, Yue H, Liu X, Dobrovolsky D, Jiang B, Wang J, Hao M, You I, Teng M, Liang Y, Hatcher J, Li Z, Manz TD, Groendyke B, Hu W, Nam Y, Sengupta S, Cho H, Shin I, Agius MP, Ghobrial IM, Ma MW, Che J, Buhrlage SJ, Sim T, Gray NS, Fischer ES. Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development. Cell, 2020, 183(6):1714.

(7).Xu D, Zhao H, Jin M, Zhu H, Shan B, Geng J, Dziedzic SA, Amin P, Mifflin L, Naito MG, Najafov A, Xing J, Yan L, Liu J, Qin Y, Hu X, Wang H, Zhang M, Manuel VJ, Tan L, He Z, Sun ZJ, Lee VMY, Wagner G, Yuan J. Modulating TRADD to restore cellular homeostasis and inhibit apoptosis. Nature, 2020, 587(7832):133.

(8).Gu J, Liu Z, Zhang S, Li Y, Xia W, Wang C, Xiang H, Liu Z, Tan L, Fang Y, Liu C, Li D. Hsp40 proteins phase separate to chaperone the assembly and maintenance of membraneless organelles. Proc. Natl. Acad. Sci. USA, 2020, 117(49):31123.

(9).Schröder M, Tan L, Wang J, Liang Y, Gray NS, Knapp S, Chaikuad A. Catalytic Domain Plasticity of MKK7 Reveals Structural Mechanisms of Allosteric Activation and Diverse Targeting Opportunities. Cell Chem. Biol., 2020, 27(10):1285.

(10).Pinch BJ, Doctor ZM, Nabet B, Browne CM, Seo HS, Mohardt ML, Kozono S, Lian X, Manz TD, Chun Y, Kibe S, Zaidman D, Daitchman D, Yeoh ZC, Vangos NE, Geffken EA, Tan L, Ficarro SB, London N, Marto JA, Buratowski S, Dhe-Paganon S, Zhou XZ, Lu KP, Gray NS. Nat. Chem. Biol., 2020, 16(9):979.

(11).Yin X, Bi R, Ma P, Zhang S, Zhang Y, Sun Y, Zhang Y, Jing Y, Yu M, Wang W, Tan L, Di W, Zhuang G, Cai MC. Multiregion whole-genome sequencing depicts intratumour heterogeneity and punctuated evolution in ovarian clear cell carcinoma. J. Med. Genet., 2020, 57(9):605.

(12).Cai MC, Zhao X, Cao M, Ma P, Chen M, Wu J, Jia C, He C, Fu Y, Tan L, Xue X, Yu Z, Zhuang G. T-cell exhaustion interrelates with immune cytolytic activity to shape the inflamed tumor microenvironment. J. Pathol., 2020, 251(2):147.

(13).Rao S, Gurbani D, Du G, Everley RA, Browne CM, Chaikuad A, Tan L, Schröder M, Gondi S, Ficarro SB, Sim T, Kim ND, Berberich MJ, Knapp S, Marto JA, Westover KD, Sorger PK, Gray NS. Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome. Cell Chem. Biol., 2019, 26(6):818.

(14) Hai-Tsang Huang, DennisDobrovolsky, Joshiawa Paulk, Guang Yang, Ellen L. Weisberg, Zainab M. Doctor,Dennis L. Buckley, Joong-Heui Cho, Eunhwa Ko, Jaebong Jang, Kun Shi, Hwan GeunChoi, James D. Griffin, Ying Li, Steven P. Treon, Eric S. Fischer, James E.Bradner, Li Tan*, Nathanael S. Gray*, AChemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinaseDegrader, Cell Chemical Biology, 2018, 25(1):88-99

(15) Li Tan#, Jun Wang#, Junko Tanizaki#,Zhifeng Huang#, Amir R. Aref#, Maria Rusan, Su-Jie Zhu, YiyunZhang, Dalia Ercan, Rachel G. Liao, Marzia Capelletti, Wenjun Zhou, WooyoungHur, NamDoo Kim, Taebo Sim, Suzanne Gaudet, David A. Barbie, Jing-Ruey JoannaYeh, Cai-Hong Yun, Peter S. Hammerman*, Moosa Mohammadi*,Pasi A. Jänne*, Nathanael S. Gray*, Development ofcovalent inhibitors that can overcome resistance to first-generation FGFRkinase inhibitors, Proceedings of the National Academy of Sciences of theUnited States of America, 2014, 111(45):E4869-4877

(16) Li Tan#, Koshi Akahane#, Randall McNally, Kathleen M. S. E. Reyskens, Scott B. Ficarro, Suhu Liu, Grit S. Herter-Sprie, Shohei Koyama, Michael J. Pattison, Katherine Labella, Liv Johannessen, Esra A. Akbay, Kwok-Kin Wong, David A. Frank, Jarrod A. Marto, Thomas A. Look, J. Simon C. Arthur, Michael J. Eck, Nathanael S. Gray*,Development of Selective Covalent Janus Kinase 3 Inhibitors, Journal ofMedicinal Chemistry, 2015, 58(16):6589-6606

(17) Li Tan, TyzoonNomanbhoy, Deepak Gurbani, Matthew Patricelli, John Hunter, Jiefei Geng, LinaHerhaus, Jianming Zhang, Eduardo Pauls, Youngjin Ham, Hwan Geun Choi, Ting Xie,Xianming Deng, Sara J. Buhrlage, Taebo Sim, Philip Cohen, Gopal Sapkota, KennethD. Westover, Nathanael S. Gray*, Discovery of type II inhibitors ofTGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinasekinase kinase 2 (MAP4K2), Journal of Medicinal Chemistry, 2015, 58(1):183-196

(18) Hideki Terai#, Li Tan#, Ellen M. Beauchamp, John M. Hatcher, QingsongLiu, Matthew Meyerson, Nathanael S. Gray*, Peter S. Hammerman*,Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated NonsmallCell Lung Cancer, ACS Chemical Biology, 2015, 10 (12):2687-2696

(19) Zhifeng Huang#, Li Tan#, Huiyan Wang#, Yang Liu, Steven Blais,Jingjing Deng, Thomas A. Neubert, Nathanael S. Gray, Xiaokun Li*, MoosaMohammadi*, DFG-out mode of inhibition by an irreversible type-1inhibitor capable of overcoming gate-keeper mutations in FGF receptors, ACSChemical Biology, 2015, 10(1):299-309

(20) Hyung-Gu Kim#, Li Tan#, Ellen L. Weisberg#, Feiyang Liu#,Peter Canning#, Hwan Geun Choi#, Scott A. Ezell, Hong Wu,Zheng Zhao, Jinhua Wang, Anna Mandinova, James D. Griffin, Alex N. Bullock,Qingsong Liu*, Sam W. Lee*, Nathanael S. Gray*,Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor, ACSChemical Biology, 2013, 8(10):2145-2150

(21) Li Tan#, DeepakGurbani#, Ellen L. Weisberg, John C. Hunter, Lianbo Li, Douglas S.Jones, Scott B. Ficarro, Samar Mowafy, Chun-Pong Tam, Suman Rao, Guangyan Du, JamesD. Griffin, Peter K. Sorger, Jarrod A. Marto, Kenneth D. Westover*, NathanaelS. Gray*, Structure-guideddevelopment of covalent TAK1 inhibitors, Bioorganic Medicinal Chemistry, 2017,25(3):838-846

(22) Li Tan#, Deepak Gurbani#, Ellen L. Weisberg#,Douglas S. Jones#, Suman Rao, William D. Singer, Faviola M. Bernard,Samar Mowafy, Annie Jenney, Guangyan Du, Atsushi Nonami, James D. Griffin, DouglasA. Lauffenburger, Kenneth D. Westover*, Peter K. Sorger*,Nathanael S. Gray*, Studies of TAK1-centered polypharmacology withnovel covalent TAK1 inhibitors, Bioorganic Medicinal Chemistry, 2017,25(4):1320-1328

(23) Li Tan, Dawei Ma, Totalsynthesis of salinamide A: a potent anti-inflammatory bicyclic depsipeptide, AngewandteChemie International Edition, 2008, 47(19):3614-3617

申请专利:

1. GrayNS and Tan L. JANUS KINASE INHIBITORS AND USESTHEREOF. WO/2015/164614.

2. GrayNS and Tan L. HYDROPHOBICALLY TAGGED JANUS KINASE INHIBITORS AND USESTHEREOF. WO/2015/164604.

3. Treon SP, Gray NS, Buhrlage SJ, Tan L and Yang G. METHODS TO TREAT LYMPHOPLASMACYTICLYMPHOMA. WO/2015/089479.

4. Treon SP, Gray NS, Buhrlage SJ, Tan L and Yang G. METHODS TO TREAT LYMPHOPLASMACYTICLYMPHOMA. WO/2015/089481.

5. Gray NS, Choi HG and Tan L. KINASE INHIBITORS FOR THE TREATMENTOF DISEASE. WO/2015/006492.

6. TreonSP, Yang G, Gray NS, Buhrlage SJ and Tan L. HCK AS A THERAPEUTIC TARGET IN MYD88 MUTATED DISEASES. PCT15/581,736

7. GrayNS, Tan L, Huang H-T, Bradner JE,Buckley D, Winter G, and Ishoey M. DEGRADATION OF PROTEIN KINASES BYCONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OFUSE. Provisional application No. 62/420,136.

中国科学院生物与化学交叉研究中心 版权所有 电话:021-68582285/68582282
地址:上海市浦东张江高科技园区海科路100号 沪ICP备05005485号-3